Last 7 days
-3.4%
Last 30 days
-16.5%
Last 90 days
-35.3%
Trailing 12 Months
-50.9%
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-09-18 | MCPEAK MERRILL A | bought | 55,600 | 5.56 | 10,000 | - |
2023-09-15 | Rothbaum Wayne P. | bought | 26,500,000 | 5.3 | 5,000,000 | - |
2023-07-14 | GRAF FINCKENSTEIN FRIEDRICH | sold (taxes) | -10,825 | 7.76 | -1,395 | chief medical officer |
2023-07-14 | Vogt Frederick G | sold (taxes) | -68,683 | 7.76 | -8,851 | interim ceo & general counsel |
2023-07-14 | GRAF FINCKENSTEIN FRIEDRICH | acquired | - | - | 2,813 | chief medical officer |
2023-07-14 | Vogt Frederick G | acquired | - | - | 20,834 | interim ceo & general counsel |
2023-07-14 | BILINSKY IGOR | sold (taxes) | -10,825 | 7.76 | -1,395 | chief operating officer |
2023-07-14 | BILINSKY IGOR | acquired | - | - | 2,813 | chief operating officer |
2023-04-14 | BILINSKY IGOR | sold (taxes) | -7,867 | 5.64 | -1,395 | chief operating officer |
2023-04-14 | GRAF FINCKENSTEIN FRIEDRICH | sold (taxes) | -7,867 | 5.64 | -1,395 | chief medical officer |
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-09-12 | Farther Finance Advisors, LLC | unchanged | - | 34.00 | 260 | -% |
2023-08-24 | PERCEPTIVE ADVISORS LLC | reduced | -8.5 | 5,090,550 | 98,816,300 | 2.86% |
2023-08-23 | WOLVERINE TRADING, LLC | added | 70.7 | 195,164 | 399,164 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | sold off | -100 | -68,432 | - | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | added | 0.61 | 16,500 | 119,480 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 47.18 | 680,504 | 1,658,430 | -% |
2023-08-16 | GTS SECURITIES LLC | new | - | 440,162 | 440,162 | 0.01% |
2023-08-16 | Nuveen Asset Management, LLC | added | 3.42 | 2,524,140 | 15,694,100 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 52.46 | 1,146,140 | 2,660,910 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | added | 3.33 | 4,000 | 24,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 17, 2023 | point72 asset management, l.p. | 4.6% | 7,347,600 | SC 13G | |
Feb 14, 2023 | avoro capital advisors llc | 4.4% | 7,020,000 | SC 13G/A | |
Feb 14, 2023 | perceptive advisors llc | 6.3% | 9,971,780 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 9.16% | 14,463,082 | SC 13G/A | |
Feb 06, 2023 | wellington management group llp | 0.27% | 421,610 | SC 13G/A | |
Feb 03, 2023 | blackrock inc. | 7.7% | 12,076,276 | SC 13G | |
Feb 02, 2023 | state street corp | 9.32% | 14,715,475 | SC 13G | |
Jan 13, 2023 | quogue capital llc | 12.52% | 2e+07 | SC 13D/A | |
Dec 30, 2022 | mhr fund management llc | 5.8% | 10,511,920 | SC 13G | |
Feb 24, 2022 | blackrock inc. | 4.7% | 7,408,505 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Sep 19, 2023 | 4 | Insider Trading | |
Sep 15, 2023 | 4 | Insider Trading | |
Sep 15, 2023 | 8-K | Current Report | |
Aug 18, 2023 | 8-K | Current Report | |
Aug 08, 2023 | 10-Q | Quarterly Report | |
Aug 08, 2023 | 8-K | Current Report | |
Jul 17, 2023 | 4 | Insider Trading | |
Jul 17, 2023 | 4 | Insider Trading | |
Jul 17, 2023 | 4 | Insider Trading | |
Jul 13, 2023 | 8-K | Current Report |
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
AMGN | 145.2B | 26.6B | 4.13% | 21.09% | 18.2 | 5.46 | 0.75% | 21.34% |
GILD | 94.5B | 27.4B | -0.16% | 19.51% | 17.24 | 3.45 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -6.80% | -20.18% | 32.68 | 3.7 | -53.67% | -91.41% |
BIIB | 37.7B | 10.0B | -1.71% | 27.59% | 14.15 | 3.78 | -6.23% | 29.40% |
MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 5.59% | 6.81% | 63.29 | 6.67 | 29.01% | 1345.90% |
BBIO | 4.5B | - | -3.04% | 140.92% | -7.66 | 48.33 | 54.84% | -12.96% |
DNLI | 3.1B | - | -4.51% | -22.98% | -23.78 | 37.44 | 122.90% | 54.78% |
BEAM | 2.0B | 80.2M | 6.46% | -52.82% | -6.01 | 24.54 | 42.17% | -39.82% |
SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | 4.38% | -25.42% | -5.13 | 12.17 | -70.36% | -531.73% |
IOVA | 1.2B | 952.0K | -16.53% | -50.89% | -2.82 | 1.2K | - | -11.27% |
REPL | 980.2M | 15.3M | -15.63% | 3.04% | -5.4 | 64.02 | 1090.59% | -36.57% |
NVAX | 664.9M | 1.6B | -12.64% | -74.33% | -1.13 | 0.42 | 23.74% | 60.24% |
VXRT | 112.7M | 2.1M | -6.14% | -67.90% | -1.12 | 54.83 | 487.70% | -8.66% |
XBIO | 8.7M | 2.2M | 58.19% | 783.63% | -2.08 | 4.04 | 45.07% | 43.77% |
IBIO | 4.1M | - | -12.28% | -96.10% | -0.05 | 3.21 | - | -129.46% |
0.5%
-6.3%
-17.3%
-47.4%
100%
90.8%
88.1%
Y-axis is the maximum loss one would have experienced if Iovance Biotherapeutics was unfortunately bought at previous high price.
Income Statement (Last 12 Months) | (In Millions) | |
---|---|---|
Description | (%) Q/Q | 2023Q2 |
Revenue | - | 1.00 |
S&GA Expenses | - | 104 |
R&D Expenses | - | 322 |
Earnings Before Taxes | - | -428 |
Net Income | - | -418 |
Balance Sheet | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Assets | -8.2% | 757 | 825 | 664 | 546 | 611 | 701 | 777 | 829 | 853 | 751 | 768 | 782 | 818 | 288 | 345 | 396 | 436 | 462 | 481 | 271 | 285 |
Current Assets | -56.9% | 275 | 638 | 479 | 370 | 432 | 490 | 508 | 583 | 667 | 605 | 636 | 724 | 783 | 256 | 316 | 367 | 411 | 445 | 475 | 266 | 280 |
Cash Equivalents | -57.7% | 230 | 544 | 232 | 118 | 108 | 92.00 | 84.00 | 59.00 | 83.00 | 132 | 67.00 | 68.00 | 161 | 53.00 | 19.00 | 39.00 | 77.00 | 54.00 | 82.00 | 81.00 | 246 |
Inventory | - | 10.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | 2.4% | 113 | 110 | 105 | 101 | 101 | 103 | 101 | 88.00 | 80.00 | 73.00 | 59.00 | 39.00 | 19.00 | 14.00 | 9.00 | 6.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 |
Liabilities | 13.2% | 179 | 158 | 164 | 152 | 138 | 149 | 156 | 130 | 108 | 103 | 112 | 70.00 | 59.00 | 45.00 | 46.00 | 41.00 | 39.00 | 27.00 | 15.00 | - | - |
Current Liabilities | 1.6% | 89.00 | 87.00 | 91.00 | 79.00 | 64.00 | 77.00 | 89.00 | 65.00 | 61.00 | 55.00 | 55.00 | 64.00 | 55.00 | 40.00 | 39.00 | 35.00 | 34.00 | 22.00 | 14.00 | 17.00 | 14.00 |
Shareholder's Equity | -13.2% | 579 | 667 | 500 | 394 | 473 | 552 | 622 | 698 | 744 | 647 | 656 | 712 | 758 | 243 | 299 | 355 | 397 | 435 | 466 | 254 | 271 |
Retained Earnings | -6.4% | -1,782 | -1,675 | -1,568 | -1,463 | -1,363 | -1,264 | -1,172 | -1,073 | -986 | -905 | -830 | -761 | -703 | -640 | -570 | -507 | -457 | -410 | 0.00 | -340 | -306 |
Additional Paid-In Capital | 0.8% | 2,360 | 2,343 | 2,069 | 1,859 | 1,839 | 1,818 | 1,795 | 1,771 | 1,731 | 1,553 | 1,487 | 1,473 | 1,461 | 883 | 869 | 0.00 | 0.00 | 845 | 839 | 594 | 577 |
Shares Outstanding | 0.1% | 225 | 224 | 188 | 158 | 157 | 157 | 157 | 156 | 154 | 149 | 148 | 147 | 146 | 127 | 126 | 126 | 124 | 123 | 123 | 97.00 | 93.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
Cashflow From Operations | -5.1% | -335 | -318 | -292 | -268 | -262 | -239 | -227 | -236 | -219 | -202 | -205 | -196 | -197 | -195 | -158 | -136 | -122 | -112 | -101 | -90.66 | -84.18 |
Share Based Compensation | -7.4% | 72.00 | 77.00 | 84.00 | 84.00 | 83.00 | 75.00 | 70.00 | 61.00 | 52.00 | 48.00 | 41.00 | 36.00 | 32.00 | 28.00 | 24.00 | 24.00 | 23.00 | 22.00 | 20.00 | 17.00 | 15.00 |
Cashflow From Investing | -78.1% | 71.00 | 323 | 256 | 325 | 264 | 9.00 | 0.00 | -10.45 | -76.16 | -340 | -317 | -349 | -293 | 189 | 90.00 | -143 | -296 | -385 | -386 | -179 | -15.98 |
Cashflow From Financing | 0.7% | 450 | 447 | 190 | 4.00 | 24.00 | 190 | 239 | 238 | 218 | 623 | 576 | 576 | 575 | 10.00 | 6.00 | 243 | 255 | 255 | 424 | 188 | 232 |
Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Condensed Consolidated Statements of Operations | ||||
Total revenue | $ 238 | $ 238 | ||
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] | Product [Member] | Product [Member] | Product [Member] | Product [Member] |
Costs and expenses | ||||
Cost of sales | $ 2,050 | $ 2,050 | ||
Research and development | 86,347 | $ 73,406 | 169,081 | $ 141,706 |
Selling, general and administrative | 21,927 | 26,328 | 50,049 | 49,741 |
Total costs and expenses | 110,324 | 99,734 | 221,180 | 191,447 |
Loss from operations | (110,086) | (99,734) | (220,942) | (191,447) |
Other income | ||||
Interest income, net | 3,081 | 385 | 6,567 | 491 |
Net Loss before income taxes | (107,005) | (99,349) | (214,375) | (190,956) |
Income tax benefit | 477 | 477 | ||
Net Loss | $ (106,528) | $ (99,349) | $ (213,898) | $ (190,956) |
Net Loss Per Share of Common Stock, Basic | $ (0.47) | $ (0.63) | $ (0.98) | $ (1.21) |
Net Loss Per Share of Common Stock, Diluted | $ (0.47) | $ (0.63) | $ (0.98) | $ (1.21) |
Weighted Average Shares of Common Stock Outstanding, Basic | 224,481 | 157,274 | 219,117 | 157,194 |
Weighted Average Shares of Common Stock Outstanding, Diluted | 224,481 | 157,274 | 219,117 | 157,194 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
---|---|---|
Current Assets | ||
Cash and cash equivalents | $ 230,010 | $ 231,731 |
Trade accounts receivable | 33 | |
Short-term investments | 20,884 | 240,114 |
Inventory | 9,720 | |
Prepaid expenses and other assets | 14,231 | 7,271 |
Total Current Assets | 274,878 | 479,116 |
Property and equipment, net | 112,549 | 105,232 |
Intangible assets, net | 235,511 | |
Operating lease right-of-use assets | 67,631 | 73,015 |
Restricted cash | 66,430 | 6,430 |
Long-term assets | 294 | 189 |
Total Assets | 757,293 | 663,982 |
Current Liabilities | ||
Accounts payable | 31,157 | 26,603 |
Accrued expenses | 46,620 | 52,295 |
Operating lease liabilities | 10,866 | 12,587 |
Total Current Liabilities | 88,643 | 91,485 |
Non-Current Liabilities | ||
Operating lease liabilities - non-current | 68,844 | 71,859 |
Deferred tax liabilities | 20,237 | |
Long-term note payable | 1,000 | 1,000 |
Total Non-Current Liabilities | 90,081 | 72,859 |
Total Liabilities | 178,724 | 164,344 |
Commitments and contingencies | ||
Stockholders' Equity | ||
Common stock, $0.000041666 par value; 500,000,000 shares authorized, 224,688,434 and 187,812,072 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | 9 | 8 |
Accumulated other comprehensive income (loss) | 325 | (902) |
Additional paid-in capital | 2,360,468 | 2,068,867 |
Accumulated deficit | (1,782,236) | (1,568,338) |
Total Stockholders' Equity | 578,569 | 499,638 |
Total Liabilities and Stockholders' Equity | 757,293 | 663,982 |
Series A Convertible Preferred Stock | ||
Stockholders' Equity | ||
Preferred stock, Value | 0 | 0 |
Series B Convertible Preferred Stock | ||
Stockholders' Equity | ||
Preferred stock, Value | $ 3 | $ 3 |